Erica L. Carpenter, Ph.D.
Affiliations: | 2009 | University of Pennsylvania, Philadelphia, PA, United States |
Area:
ImmunologyGoogle:
"Erica Carpenter"Parents
Sign in to add mentor| Robert H. Vonderheide | grad student | 2009 | Penn | |
| (Lymphocyte response and dysregulation in human cancer.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Thompson JC, Scholes DG, Carpenter EL, et al. (2023) Molecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors. British Journal of Cancer |
| Magbanua MJM, van 't Veer L, Clark AS, et al. (2023) Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study. Breast Cancer Research and Treatment |
| Narayan V, Barber-Rotenberg JS, Jung IY, et al. (2022) PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nature Medicine |
| Thompson JC, Carpenter EL, Silva BA, et al. (2021) Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy. Jco Precision Oncology. 5 |
| O'Hara MH, O'Reilly EM, Varadhachary G, et al. (2021) CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. The Lancet. Oncology. 22: 118-131 |
| Reiss KA, Wattenberg MM, Damjanov N, et al. (2020) A Pilot Study of Galunisertib Plus Stereotactic Body Radiotherapy in Patients with Advanced Hepatocellular Carcinoma. Molecular Cancer Therapeutics |
| Aggarwal C, Thompson JC, Carpenter EL. (2020) Plasma Tumor Mutation Burden and Response to Pembrolizumab-Response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 26: 3492 |
| Lin JH, Huffman AP, Wattenberg MM, et al. (2020) Type 1 conventional dendritic cells are systemically dysregulated early in pancreatic carcinogenesis. The Journal of Experimental Medicine. 217 |
| Bagley SJ, Carpenter EL. (2020) Plasma cfDNA in Glioblastoma-Response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 26: 2276 |
| Aggarwal C, Thompson JC, Chien AL, et al. (2020) Baseline plasma tumor mutation burden predicts response to pembrolizumab-based therapy in patients with metastatic non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |